Urticaria – Landscape & Forecast – Disease Landscape & Forecast (G7)

The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). However, both drug classes can have serious side effects, and many patients still struggle to control their lesions. The approval of Xolair, and more recently Dupixent in Japan, have provided treatment options for some of these patients, and clinical trials for additional therapies are underway. With only one targeted therapy (Xolair) currently approved across the G7 countries, the most important factors driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.

Questions answered

• What is the physician perspective on antihistamines for chronic urticaria? How frequently are these therapies prescribed?
• How do physicians diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are CIndU and CSU treated similarly, or is the treatment algorithm distinct?
• Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
• How does Novartis / Roche’s Xolair—approved for CSU—perform, and how will emerging biologics and targeted oral agents compare?

Geography: United States, EU5, Japan

Primary research: 25 country-specific interviews with thought-leading dermatologists and allergists; supported by survey data collected for this and other Clarivate research

Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated chronic spontaneous urticaria and chronic inducible urticaria patients

Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2033, segmented by brands / generics and epidemiological subpopulations (chronic spontaneous urticaria and chronic inducible urticaria)

Emerging therapies: Phase 3/PR: 3 drugs

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.